Bugworks Research starts first human dose study to treat critical bacterial infections
Bugworks Research starts first human dose study to treat critical bacterial infectionsBengaluru : Bugworks Research announced that the first human dose was administered in a phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), supported by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
DoP releases draft policy to catalyse R&D and innovation in pharma-MedTech sector
The draft policy aims to encourage R&D in Pharma-MedTech sector, and promoting innovation for India to become a leader in drug discovery and innovative medical devices through incubating an entrepreneurial environment. The department has invited comments from the stakeholders by November 6, 2021.
Union Minister of Health and Family Welfare, GoI, launches first commercial batch of COVAXIN® manufactured in Ankleshwar, Gujarat
Bharat Biotech, a global leader in vaccine development and innovation, today announced the commercial launch of the first batch of COVAXIN® from its Chiron Behring Vaccines facility in Ankleshwar, Gujarat. Hon’ble Union Health Minister of Health and Family Welfare Shri. Mansukh Mandaviya inaugurated the COVAXIN® batches.
IVI and Bharat Biotech launch Global Chikungunya Vaccine Phase II/III trial in Costa Rica
IVI is leading the Global Chikungunya vaccine Clinical Development Program (GCCDP) consortium in partnership with Bharat Biotech and with support from the Coalition for Epidemic Preparedness Innovations (CEPI) and Ind-CEPI.